Moneycontrol Be a Pro
Get App
SENSEX NIFTY
Unichem Laboratories > Company History > Pharmaceuticals > Company History of Unichem Laboratories - BSE: 506690, NSE: UNICHEMLAB
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - Unichem Laboratories

Unichem Laboratories

BSE: 506690|NSE: UNICHEMLAB|ISIN: INE351A01035|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Dec 06, 16:00
155.50
-6.55 (-4.04%)
VOLUME 5,040
LIVE
NSE
Dec 06, 15:57
155.90
-5.7 (-3.53%)
VOLUME 37,970
Company History - Unichem Laboratories
YEAR                                                    EVENTS
 1962 - The Company was incorporated on 22nd August, at Bombay.
 
      - The Company manufactures pharmaceutical products and chemicals
 on
        behalf of Uni-U.C.B.(India) Pvt.Ltd., associates of the
 reputed
        UCB of Brussels, Belgium.
 
      - Government approved the scheme to manufacture dextran and iron
  
        dextran cycoside in collaboration with Roshkilde Medical
 Company
        of Denmark. 
 
      - Government also approved the Collaboration Scheme with Shofu
        Dental Mfg.Co.Ltd., Japan, for the manufacture of dental
        products.
 
      - The Company was formed to take over as a going concern the
        propreitory business carried on since 1944, at Bombay, by Shri
 A
        V Mody as manufacturing chemist and dealer in pharmaceuticals
 and
        medicines, under the name and style of 'Unichem
 Laboratories'.
 
 1983 - The Upjohn division was established, the name was changed to
        UNISEARCH division with effect from 1st October, 1987.  This
 was
        to market selected specialities of Upjohn, UCB and Unichem.
 
 1992 - Unichem Exports Limited ceased to be a subsidiary of the 
 company 
        from  17th November.
   
 1993 - The Company introduced a new antibiotic in the market, and 
        incurred substantial cost on the new launch. 
 
 1994 - The Company made an Issue of Equity Shares to the
 shareholders,
        promoters and employees as a result of which the Equity share 
      
        Capital has increased to Rs.199.12 lacs.  
 
 1995 - The Pharma Division extended its products range by launching
 two
        new molecules and one additional formulation in the market.
 
      - 5,59,900 No. of Equity Warrants were allotted to th
        Promoters/Promoter Group.
 
 1998 - The Company has launched three new products in three
 different
        therapeutic areas i.e. Cardiovascular, Anti Inflammatory and
 Anti
        oxidant under the brand names CORVADIL-A, PRONIM and
 PRO-RIDAGE. 
 
      - The company has a technical collaboration with Shofu Dental
        Manufacturing Co, Japan and Roshkilde Medical Co, Denmark.
 
      - The Company has launched three new products in three
 different
        therapeutic areas viz., Satin a cholesterol reducer in the
 area
        of cardiovascular therapeutic segment; Domadol in the post
        operative pain management segment and Zonep in the psychiatry
        segment.
 
      - The company recently commissioned a Rs 20-crore manufacturing
        facility at Bardez in Goa, specially designed to meet
 stringent
        standards in export markets.
 
 1999 - The Company's new Division mainly catering to Women's
 Healthcare
        called FOREVA was launched on 1st April. 
 
      - The Company has launched eight new products, Losar, Serta,
        Biclar, Zisper, M-cam, Flospar, Lanpro, Anticox 3.
 
      - Unichem Laboratories, a leading pharmaceutical company, has
        launched `M-Cam', a non-steroidal anti-inflammatory drug
        (NSAID) for the treatment or arthritis.
 
      - The company has recently commissioned its multi-purpose
        facility at Roha in Maharashtra to manufacture a range of
 bulk
        drugs scheduled to go off patent in advanced markets by 2000.
 
 
      - The company has tied up with Aptech and NIIT to reach a
        majority of the nearly 3,000 cardiologists and over 20,000
        physician MDs in the country.
 
 2000 - Unichem Laboratories has entered into a strategic alliance
 with
        the Korean Green Cross Corporation to market Urokinase.
 
      - The Company has introduced Celib for management of arthritis.
        The Company has launched a website on Celib for doctors and
        patients called www.celibunichem.com.
 
      - Unichem Laboratories has launched Zulu, the first muscle
 relaxant
        containing nimesulide and tizanidine.
 
      - The Foreva, the Women's healthcare division of the company
 has
        acquired the marketing and distribution rights for Partobulin
        (Anti-D Immunoglobulin) in India from Baxter Healthcare.
 
     - The Company will launch its own version of Pfizer's impotence
 pill Viagra
        under the brand name Erix.
 
 2001 - Foreva, the women's healthcare division of Unichem
 Laboratories, has entered
             into a technical tie-up with the US-based Protein
 Technologies International Inc, a
             DuPont division, for developing a soya protein supplement
 for women called Nutreva.
 
 2002
 
 -Enters into Joint Venture with the former Directors of the Bioglan
 group in Ireland.
 
 -Bharat Bio signs marketing alliance with the company to market
 hepatitis-B, recombinant.
 
 -Ind-Swift ties up with the company for Co-marketing pact to
 co-market finished dosages of its anti-depressant drug citalopram 
 
 2003
 
 -Registered a net profit increase by around 10.6% in the I quarter at
 Rs.9.4crs for the same period last year.
 
 -Enters into an agreement for the sale of its Animal Healthcare
 Division to M/s Tetragon Chemie Ltd.
 
 -Appoints Mr Prafful  D Sheth as the Director of the company.
 
 -Unichem Laboratories Ltd, a Mumbai based Rs 475-crore pharmaceutical
 company, has received ISO 9001 & 14001 certificates
 
 - On April 20, 2005 announces commencement of production at its
 second unit at Baddi, Himachal Pradesh.
 
 2006
 
 -Unichem Laboratories enters into agreement with PLIVA inc, USA
 
 2009
 
 - Unichem Laboratories Ltd has appointed Mr. Harcharan Singh as Chief
 Executive - Pharma with effect from March 24, 2009. He shall report to
 the Board.
 
 2010
 
 -Unichem Laboratories Ltd has received approval from US Food & Drug
 Administration (U.S. FDA) for Hydrochlorothiazide Capsules in the
 strengths of 12.5 mg.
 
 -Unichem Laboratories Ltd strengthened 6.38% to close at Rs 381.15 as
 the company has received EU GMP certificate from IRISH Medicines Board
 for the 12 API's manufactured at Company's Roha plant.
 
 -Company has splits its Face value of Shares from Rs 5 to Rs 2
 
 2011
 
 -Unichem Laboratories Ltd has received approval from US Food & Drug
 Administration (FDA) for Divalproex Sodium Delayed Release Tablets
 USP 125mg, 250mg and 500mg (Valproic -Acid Activity).
 
 
 2012
 
 -Mr. Bhagwat S. Dhingra has been appointed as Chief Executive -
 Domestic Pharma.
 
 -Unichem Laboratories receives ANDA tentative approval from USFDA for
 IRBESARTAN TABLETS.
 
 -Unichem gets tentative nod from USFDA for dementia tablets.
 
 2013
 -Unichem Laboratories receives ANDA approval from USFDA for
 Amlodipine Besylate Tablets.
 -Unichem Laboratories has recommended Dividend of Rs. 4.50 (225%) per
 equity share of Rs. 2/- each.
 
 2014
 -Unichem Laboratories receives ANDA approval from USFDA for
 Metronidazole USP Tablets.
 -Unichem Laboratories has recommended Final Dividend of Rs. 4/-
 (200%) per equity share of Rs. 2/- each .
 
 
 
 
Source : Dion Global Solutions Limited
Quick Links for Unichem Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.